Hair Loss Protocols That Actually Work: A Clinical Breakdown

"Hair loss is one of the most emotionally loaded complaints a patient can bring to your office. They've usually tried everything they've seen on social media before they sit down with you. Our job is to cut through the noise and build a protocol grounded in biology, not marketing."

— Dr. Luca Ferretti, Curara

Few conditions sit at the intersection of medicine and identity quite like hair loss. By age 50, roughly half of men and a quarter of women experience clinically significant thinning. The global hair restoration market is projected to exceed $13 billion by 2028, fueled in large part by a flood of consumer products making bold claims with thin evidence.

For practitioners, the challenge isn't a lack of treatments — it's knowing which ones are backed by rigorous data, how to combine them into coherent protocols, and when to set realistic expectations. Dr. Luca Ferretti, who oversees hair restoration programs at Curara, has spent the last decade refining clinical approaches that balance efficacy, safety, and patient adherence.

Here's what actually works.

Understanding the Biology of Hair Loss

Androgenetic alopecia (AGA) accounts for over 90% of hair loss in both men and women, though the presentation differs. In men, it typically follows the familiar Norwood pattern — receding temples, thinning crown, eventual confluence. In women, it tends to present as diffuse thinning along the Ludwig scale, often preserving the frontal hairline while the part widens.

The core mechanism is the same: genetically susceptible hair follicles miniaturize in response to dihydrotestosterone (DHT), a potent androgen converted from testosterone by the enzyme 5-alpha reductase. Over successive growth cycles, affected follicles produce thinner, shorter, less pigmented hairs until they eventually stop producing visible hair altogether.

"Understanding this timeline is critical for setting patient expectations," Dr. Ferretti emphasizes. "Miniaturization happens over years. Reversal — when it's possible — also takes time. Any protocol that promises visible results in four weeks is selling something other than science."

First-Line Treatments: The Proven Foundation

Finasteride and Dutasteride

Finasteride (1 mg daily) remains the most evidence-supported oral treatment for male AGA. It inhibits type II 5-alpha reductase, reducing scalp DHT levels by approximately 60-70%. In pivotal trials, 83% of men maintained or increased hair count at two years, and 66% showed visible improvement versus placebo. Dutasteride (0.5 mg daily) inhibits both type I and type II 5-alpha reductase, reducing DHT by over 90%, and has shown superior hair count improvements in head-to-head trials.

The conversation around sexual side effects requires nuance. Controlled trials report rates of 1-2% for decreased libido, erectile dysfunction, and reduced ejaculate volume — comparable to placebo in most studies. The "nocebo effect" is well-documented: patients who are warned about side effects are significantly more likely to report them. Dr. Ferretti's approach is straightforward.

"I discuss side effects honestly but in context. The data shows these medications are well-tolerated by the vast majority of patients. I present the numbers, let the patient decide, and monitor closely. Most of the fear around finasteride is driven by internet forums, not clinical evidence."

— Dr. Luca Ferretti

For female patients, finasteride is used off-label (typically 2.5-5 mg daily) and only in postmenopausal women or those on reliable contraception, given the teratogenicity risk. Spironolactone (100-200 mg daily) is the more common anti-androgen choice for premenopausal women with AGA.

Minoxidil

Topical minoxidil (5% for men, 2% or 5% for women) is the other cornerstone therapy, FDA-approved since 1988. It works through a different mechanism than finasteride — primarily by prolonging the anagen (growth) phase of the hair cycle and increasing follicular blood flow through potassium channel opening and upregulation of vascular endothelial growth factor (VEGF).

The clinical reality: minoxidil works, but compliance is its Achilles' heel. Twice-daily topical application is messy, can irritate the scalp, and leaves residue. Dr. Ferretti estimates that fewer than 40% of patients maintain consistent application beyond six months — and inconsistent use produces inconsistent results.

This compliance gap is one reason oral minoxidil has gained significant traction (more on that in the emerging treatments section below).

Advanced Therapies: PRP and Laser

Platelet-Rich Plasma (PRP)

PRP therapy for hair loss involves drawing the patient's blood, concentrating the platelet fraction via centrifugation, and injecting it into the scalp at the level of the hair follicle. The concentrated growth factors — PDGF, TGF-beta, VEGF, EGF — are thought to stimulate follicular stem cells, extend anagen phase, and increase perifollicular vascularity.

The evidence base has strengthened considerably. A 2023 systematic review in the Journal of the American Academy of Dermatology analyzed 22 randomized controlled trials and found that PRP significantly improved hair density compared to placebo in both male and female AGA, with a weighted mean increase of 33.6 hairs per square centimeter.

The caveats: PRP protocols vary widely between clinics (single vs. double spin, platelet concentration, injection depth, frequency), and this heterogeneity makes it difficult to compare results across studies. Dr. Ferretti uses a standardized protocol of three monthly sessions followed by quarterly maintenance.

"PRP is not a standalone treatment. I position it as an accelerator — it amplifies the results you're getting from finasteride and minoxidil. Patients who want PRP alone without the foundational medications are usually disappointed."

— Dr. Luca Ferretti

Low-Level Laser Therapy (LLLT)

LLLT devices — including laser caps, helmets, and combs — deliver red or near-infrared light (typically 650-670 nm) to the scalp. The proposed mechanism involves photobiomodulation of mitochondrial cytochrome c oxidase, increasing ATP production and stimulating cellular activity in the follicular bulge.

Several FDA-cleared devices have shown modest but statistically significant improvements in hair density in controlled trials. A meta-analysis of 11 RCTs found a mean increase of 17.2 hairs per square centimeter over 24 weeks. Results are most pronounced in patients with early-stage thinning. LLLT is best used as an adjunct, not a primary therapy.

Nutritional Factors: What the Evidence Supports

The supplement industry markets heavily to hair loss sufferers, but only a handful of nutritional interventions have meaningful clinical support:

• Iron (ferritin): Iron deficiency is the most common nutritional cause of hair loss, particularly in premenopausal women. Telogen effluvium frequently presents when ferritin drops below 30 ng/mL, even when hemoglobin remains normal. Repletion to ferritin levels above 70 ng/mL is associated with hair recovery in deficient patients.
• Zinc: Zinc deficiency is associated with diffuse hair loss and telogen effluvium. Serum zinc levels below 70 mcg/dL warrant supplementation (30-50 mg elemental zinc daily). Over-supplementation can impair copper absorption, so monitoring is important.
• Vitamin D: Vitamin D receptors play a role in hair follicle cycling. Observational studies consistently show lower vitamin D levels in AGA patients. While supplementation trials are limited, optimizing 25-OH vitamin D to 40-60 ng/mL is reasonable practice given the broader health benefits.
• Biotin: Despite its popularity, biotin supplementation only benefits patients with actual biotin deficiency — which is rare. It does, however, interfere with many immunoassays, producing falsely abnormal results for thyroid panels, troponin, and hormone levels. Patients should stop biotin 72 hours before lab work.

"I check ferritin, zinc, vitamin D, and thyroid on every hair loss patient," Dr. Ferretti says. "Not because supplements are the answer, but because deficiencies can sabotage an otherwise excellent protocol."

Emerging Treatments Gaining Clinical Ground

Oral Minoxidil

Low-dose oral minoxidil (1.25-5 mg daily) has become one of the most significant shifts in hair loss treatment. It eliminates the compliance problem of topical application entirely and appears to produce equal or superior results. A landmark 2022 randomized trial in the New England Journal of Medicine found that oral minoxidil 5 mg was non-inferior to topical minoxidil 5% in men with AGA, with significantly higher patient satisfaction.

The trade-off is systemic side effects: hypertrichosis (unwanted body hair growth) occurs in roughly 15-20% of patients, and cardiovascular monitoring is prudent given minoxidil's origins as an antihypertensive. Dr. Ferretti starts at 1.25 mg daily and titrates up, monitoring blood pressure and heart rate at follow-ups.

Topical Finasteride

Topical finasteride formulations (typically 0.1-0.25%) aim to reduce scalp DHT while minimizing systemic absorption and the associated side effect profile. Early clinical data is promising — a 2023 phase III trial showed topical finasteride 0.25% achieved 80% of the hair count improvement of oral finasteride 1 mg, with significantly lower serum DHT suppression. This could become a preferred option for patients concerned about systemic effects.

Exosome Therapy

Exosome-based treatments — using extracellular vesicles derived from mesenchymal stem cells — are the newest entrant in the hair restoration space. Preclinical data shows that exosomes can activate dermal papilla cells, promote angiogenesis, and extend anagen phase. Early pilot studies in humans show promising results, but large-scale controlled trials are still needed. Dr. Ferretti considers exosomes "worth watching but not yet ready for routine clinical use."

Beyond Androgens: Hormonal and Systemic Causes

Not all hair loss is androgenetic. A thorough workup should evaluate:

• Thyroid dysfunction: Both hypothyroidism and hyperthyroidism can cause diffuse hair loss. TSH, free T3, free T4, and thyroid antibodies should be part of every initial hair loss panel.
• PCOS and hyperandrogenism: Women with polycystic ovary syndrome often present with hair thinning alongside other androgenic symptoms. Total and free testosterone, DHEA-S, and androstenedione help clarify the picture.
• Stress-related telogen effluvium: Acute physiological or emotional stress can trigger widespread shedding 2-4 months after the inciting event. This is usually self-limited but can unmask underlying AGA.
• Autoimmune alopecia areata: Patchy, well-demarcated hair loss suggests alopecia areata, which requires a fundamentally different treatment approach (JAK inhibitors, intralesional steroids). Don't treat alopecia areata with an AGA protocol.
• Medication-induced loss: Numerous medications can contribute to hair thinning — anticoagulants, retinoids, certain antidepressants, beta-blockers, and chemotherapeutics. A thorough medication review is essential.

A Practical Protocol for Practitioners

Dr. Ferretti's framework for building a hair loss protocol in clinical practice:

Step 1: Diagnose Accurately

Take a thorough history (onset, pattern, family history, medications, stressors). Perform a scalp examination. Order baseline labs: CBC, ferritin, zinc, vitamin D, TSH, free T3/T4, testosterone (total and free), DHEA-S, and a metabolic panel. Consider a scalp biopsy if the diagnosis is unclear.

Step 2: Address Deficiencies First

Correct any nutritional deficiencies or hormonal imbalances before layering on hair-specific treatments. A patient with a ferritin of 15 needs iron repletion regardless of whether they also have AGA.

Step 3: Build the Foundation

For AGA: start with either oral finasteride (or spironolactone for premenopausal women) plus minoxidil (oral or topical based on patient preference and compliance likelihood). Set expectations: 3-6 months for stabilization, 6-12 months for visible improvement.

Step 4: Layer Adjunct Therapies

If the patient wants to accelerate results and budget allows, add PRP (three monthly sessions, then quarterly) and/or LLLT (at-home device, 3-4 sessions per week). These enhance outcomes from the foundational medications but don't replace them.

Step 5: Monitor and Adjust

Photograph the scalp at baseline and every 3 months using consistent lighting and positioning. Recheck labs at 6 and 12 months. Adjust the protocol based on response, side effects, and patient goals.

"The practitioners who get the best results treat hair loss like any other chronic condition — with a systematic protocol, consistent monitoring, and clear communication about realistic timelines. There are no shortcuts, but there are very effective tools."

— Dr. Luca Ferretti

Hair loss treatment has never been more evidence-based or more effective than it is right now. The gap isn't in the available treatments — it's in the structured, disciplined application of those treatments within a clinical framework. Practitioners who build thoughtful protocols and set honest expectations will earn patients who stay for the long term.